Citrine Global Corp. Reports $3.1 Million Net Loss for Fiscal Year 2023

Citrine Global Corp. reported a net loss of $3.1 million for the fiscal year ending December 31, 2023, an increase from a net loss of $2.6 million in the previous year. The company did not generate any revenue during this period, maintaining a consistent trend from the prior year. Research and development expenses decreased slightly to $96,000 from $120,000, while marketing and general administrative expenses rose to $2.2 million from $1.9 million, primarily due to increased share-based compensation and costs associated with executive consulting agreements.

The company’s financial position showed a cash balance of $7,000 and a working capital deficiency of $2.5 million as of December 31, 2023, compared to a cash balance of $77,000 and a working capital deficiency of $1.6 million in 2022. The increase in working capital deficiency was attributed to higher accrued compensation and other liabilities. Net cash used in operating activities decreased to $199,000 from $567,000 in the previous year, reflecting significant non-cash expenses.

Citrine Global has been actively pursuing strategic developments, including a 19% equity stake acquisition in iBOT Israel Botanicals Ltd. for $10 million, which was executed on December 31, 2023. The company also holds a 10% equity interest in MyPlant Bio Ltd. and has options to increase its stake in both companies. The ongoing conflict in Israel, which began on October 7, 2023, has significantly impacted the company's operations and strategic initiatives, including delays in product launches and international expansion plans.

Operationally, Citrine Global is focused on establishing its Green Vision Center in Yerucham, Israel, which is intended to serve as an innovation and production hub for plant-based wellness and pharmaceutical products. The center is supported by a government grant of approximately $3.4 million, aimed at covering eligible expenses related to construction and equipment. The company is also exploring international sales channels, particularly in the U.S. market, although execution has been hampered by the current geopolitical situation.

Looking ahead, Citrine Global's management is assessing the ongoing impacts of the conflict on its operations and financial stability. The company plans to continue its focus on product development and market entry, particularly in the wellness and pharmaceutical sectors, which are projected to experience significant growth. However, the company acknowledges the uncertainty surrounding its ability to achieve profitability and generate revenue in the near term, given the current economic and operational challenges.